Noom MedvsFound Weight Loss Program

Noom Med combines two things. First, a licensed clinician reviews an online health assessment and, if appropriate, prescribes a weight-management medication: a compounded or brand-name GLP-1 receptor agonist (semaglutide, the active ingredient in Ozempic/Wegovy), a dual GLP-1/GIP receptor agonist (tirzepatide, the active ingredient in Mounjaro/Zepbound), or an oral option such as metformin. GLP-1 medications mimic a gut hormone that curbs appetite, slows stomach emptying so you feel full longer, and helps regulate blood sugar; tirzepatide adds a second incretin pathway (GIP). Metformin works differently, mainly by reducing the liver's glucose output and improving insulin sensitivity. Second, the Noom app delivers daily cognitive-behavioral-therapy-style lessons on food psychology, habit formation, and emotional eating, plus 1:1 and group coaching, to support the lifestyle changes that help weight-loss results last.

After an online intake and Found's MetabolicPrint assessment, a licensed clinician reviews your profile and prescribes a GLP-1 when appropriate. Cash-pay plans include compounded semaglutide or tirzepatide; branded GLP-1s can be prescribed but are billed separately. These drugs act on GLP-1 (and, for tirzepatide, GIP) receptors to reduce appetite and slow gastric emptying. The Found app delivers behavioral coaching, an AI health companion, and community support throughout.

The medications Noom prescribes carry strong trial evidence, though that evidence comes from the full-dose, FDA-approved products rather than compounded or microdose versions. In the STEP 1 trial (New England Journal of Medicine, 2021), once-weekly semaglutide 2.4 mg plus lifestyle intervention produced a mean 14.9% body-weight loss at 68 weeks versus 2.4% with placebo, with about 69% of treated participants losing at least 10% of their body weight. In SURMOUNT-1 (New England Journal of Medicine, 2022), tirzepatide produced average weight loss of roughly 16.0% to 22.5% depending on dose. Important caveats: Noom's lower-priced plans use compounded GLP-1s, and its Microdose plan deliberately uses doses below the standard maintenance levels studied in these trials, so individual results may be smaller than the headline trial figures. Noom's own 2026 engagement report (observational, 14,203 GLP-1 program members) found that the most-engaged app users lost about 8.3 lbs more by week 40 and stayed on their medication roughly twice as long (about 2.2x) over the first year compared with the least engaged, but the company itself notes this shows correlation, not proof that the app causes the difference. Individual results vary.

The GLP-1 actives Found uses are the same molecules studied in landmark trials, where semaglutide produced roughly 15% mean weight loss (STEP 1) and tirzepatide up to about 21% (SURMOUNT-1). However, compounded formulations are not FDA-approved and have not been individually tested for the brand-name trial endpoints, so results may differ. Individual results vary.

The most common GLP-1 and tirzepatide side effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, abdominal pain, and reflux, usually worst when starting or increasing the dose and often easing over time. Lower-dose (microdose) regimens are marketed partly to blunt these effects, though that benefit is not established in large trials. Serious but less common risks include pancreatitis, gallbladder problems such as gallstones, kidney injury from dehydration, and, in rodent studies, thyroid C-cell tumors, which is why these drugs carry a boxed warning; a causal link to thyroid cancer in humans has not been established. A specific concern with compounded semaglutide: the FDA has warned of dosing errors in which patients received 5 to 20 times the intended dose from multi-dose vials, with adverse events including severe vomiting, fainting, dehydration, and some hospitalizations. Follow dosing instructions exactly, report severe or persistent abdominal pain promptly, and seek medical care for any serious reaction.

GLP-1 medications commonly cause nausea, constipation, and diarrhea, usually most pronounced during dose increases. Serious but rare risks include pancreatitis and gallbladder disease. Because cash plans use compounded products, ask about the compounding pharmacy and ingredients. This is educational, not medical advice.

As of 2026, Noom Med medication-included plans (priced after a discounted first month and typically billed quarterly) run roughly: the Weight-Loss Pill (metformin) plan around $99/month, the compounded GLP-1Rx plan around $129/month, the compounded Microdose GLP-1Rx plan around $199/month, and the tirzepatide dual-agonist GLP-1Rx Plus plan around $299/month. A separate telehealth tier (around $99/month after the first month) covers clinician care and the app for brand-name drugs such as Ozempic, Wegovy, Mounjaro, or Zepbound, but the medication itself is billed separately through insurance or cash pay (brand-name GLP-1s can list at roughly $1,000 or more per month without coverage). Plans are generally FSA/HSA-eligible. Insurance rarely covers the bundled program or compounded drugs, so expect this to be a recurring out-of-pocket cost; confirm current pricing on Noom's site before enrolling, as plans and prices change.

As of 2026, membership is advertised 'as low as $49/mo,' with a common 3-month Kickstart at first-month-free then $129/mo for self-pay members. Compounded GLP-1 is included in cash-pay plans; branded drugs cost extra. Kickstart excludes Medicare/Medicaid/TriCare enrollees.

Noom Med is aimed at US adults who qualify for prescription weight management, typically a BMI of 30 or higher (obesity) or 27 or higher (overweight) with a weight-related condition such as type 2 diabetes, high blood pressure, or sleep apnea; final eligibility is determined by the clinician after intake, and clinical guidelines, not a website, govern who should be treated. It is not appropriate for people who are pregnant or breastfeeding, those with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome, those with a history of pancreatitis, or anyone with known hypersensitivity to the prescribed drug. Anyone with gallbladder disease, diabetic retinopathy, severe kidney or liver disease, or significant gastrointestinal disorders should disclose this to the clinician. People who specifically want an FDA-approved drug should choose the brand-name telehealth tier rather than the compounded plans. The compounded Microdose plan is also unavailable in some states (such as Alabama, Arkansas, Iowa, Louisiana, and Mississippi) due to state rules on compounded medications.

Prospective members complete an online health quiz and metabolic assessment; a licensed clinician makes the final prescribing decision based on GLP-1 eligibility guidelines (typically BMI 30+, or 27+ with a related condition). Kickstart self-pay pricing is not available to those with in-network insurance or government plans.